{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:17:24Z","timestamp":1787008644611,"version":"build-2736575974"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2019,4,27]],"date-time":"2019-04-27T00:00:00Z","timestamp":1556323200000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"crossref","award":["20120229"],"award-info":[{"award-number":["20120229"]}],"id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"crossref","award":["NCT01785849"],"award-info":[{"award-number":["NCT01785849"]}],"id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"crossref","award":["20120230"],"award-info":[{"award-number":["20120230"]}],"id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"crossref","award":["NCT01788046"],"award-info":[{"award-number":["NCT01788046"]}],"id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"crossref","award":["20120360"],"award-info":[{"award-number":["20120360"]}],"id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"crossref","award":["NCT1896232"],"award-info":[{"award-number":["NCT1896232"]}],"id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Etelcalcetide is an intravenous calcimimetic approved for treatment of secondary hyperparathyroidism (sHPT) in patients receiving hemodialysis. Besides lowering parathyroid hormone (PTH), etelcalcetide also significantly reduces fibroblast growth factor 23 (FGF23), but the mechanisms are unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>To investigate potential mediators of etelcalcetide-induced FGF23 reduction, we performed secondary analyses of the 26-week randomized trials that compared the effects on PTH of etelcalcetide (n\u2009=\u2009509) versus placebo (n\u2009=\u2009514) and etelcalcetide (n\u2009=\u2009340) versus cinacalcet (n\u2009=\u2009343) in adults with sHPT receiving hemodialysis. We analyzed changes in FGF23 in relation to changes in PTH, calcium, phosphate and bone turnover markers. We also investigated how concomitant treatments aimed at mitigating hypocalcemia altered the FGF23-lowering effects of etelcalcetide.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Etelcalcetide reduced FGF23 [median % change (quartile 1\u2013quartile 3)] from baseline to the end of the trial significantly more than placebo [\u201356% (\u201385 to \u20137) versus +2% (\u201340 to +65); P\u2009&amp;lt;\u20090.001] and cinacalcet [\u201368% (\u201387 to \u201326) versus \u201341% (\u201376 to +25); P\u2009&amp;lt;\u20090.001]. Reductions in FGF23 correlated strongly with reductions in calcium and phosphate, but not with PTH; correlations with bone turnover markers were inconsistent and of borderline significance. Increases in concomitant vitamin D administration partially attenuated the FGF23-lowering effect of etelcalcetide, but increased dialysate calcium concentration versus no increase and increased dose of calcium supplementation versus no increase did not attenuate the FGF23-lowering effects of etelcalcetide.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These data suggest that etelcalcetide potently lowers FGF23 in patients with sHPT receiving hemodialysis and that the effect remains detectable among patients who receive concomitant treatments aimed at mitigating treatment-associated decreases in serum calcium.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ckj\/sfz034","type":"journal-article","created":{"date-parts":[[2019,3,21]],"date-time":"2019-03-21T00:20:05Z","timestamp":1553127605000},"page":"75-84","source":"Crossref","is-referenced-by-count":25,"title":["Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis"],"prefix":"10.1093","volume":"13","author":[{"given":"Myles","family":"Wolf","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Nephrology, Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey A","family":"Block","sequence":"first","affiliation":[{"name":"Denver Nephrology, Research Divsion, Denver, CO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn M","family":"Chertow","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Nephrology, Stanford University School of Medicine, Palo Alto, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry","family":"Cooper","sequence":"first","affiliation":[{"name":"Amgen, Inc., Thousand Oaks, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Fouqueray","sequence":"first","affiliation":[{"name":"Amgen, Inc., Thousand Oaks, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon M","family":"Moe","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Nephrology, Indiana University School of Medicine, Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Sun","sequence":"first","affiliation":[{"name":"Amgen, Inc., Thousand Oaks, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Tomlin","sequence":"first","affiliation":[{"name":"Amgen, Inc., Thousand Oaks, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4607-9415","authenticated-orcid":false,"given":"Marc","family":"Vervloet","sequence":"first","affiliation":[{"name":"Department of Nephrology, VU University Medical Center, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Oberbauer","sequence":"first","affiliation":[{"name":"Department of Nephrology, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,4,26]]},"reference":[{"key":"2020021705393533000_sfz034-B1","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/ki.2012.176","article-title":"Update on fibroblast growth factor 23 in chronic kidney disease","volume":"82","author":"Wolf","year":"2012","journal-title":"Kidney Int"},{"key":"2020021705393533000_sfz034-B2","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1681\/ASN.2005010052","article-title":"Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease","volume":"16","author":"Gutierrez","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"2020021705393533000_sfz034-B3","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1681\/ASN.2005111185","article-title":"Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D","volume":"17","author":"Liu","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"2020021705393533000_sfz034-B4","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1525-139X.2007.00308.x","article-title":"Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease","volume":"20","author":"Stubbs","year":"2007","journal-title":"Semin Dial"},{"key":"2020021705393533000_sfz034-B5","doi-asserted-by":"crossref","first-page":"F282","DOI":"10.1152\/ajprenal.90742.2008","article-title":"FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1","volume":"297","author":"Gattineni","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"key":"2020021705393533000_sfz034-B6","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/MNH.0b013e328338f536","article-title":"Recent advances in the rapidly evolving field of fibroblast growth factor 23 in chronic kidney disease","volume":"19","author":"Zisman","year":"2010","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2020021705393533000_sfz034-B7","doi-asserted-by":"crossref","first-page":"F351","DOI":"10.1152\/ajprenal.00232.2013","article-title":"Regulation of renal phosphate transport by FGF23 is mediated by FGFR1 and FGFR4","volume":"306","author":"Gattineni","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"2020021705393533000_sfz034-B8","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.abb.2014.06.031","article-title":"Bone-kidney axis in systemic phosphate turnover","volume":"561","author":"Razzaque","year":"2014","journal-title":"Arch Biochem Biophys"},{"key":"2020021705393533000_sfz034-B9","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1053\/j.ajkd.2004.04.029","article-title":"Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency","volume":"44","author":"Shigematsu","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"2020021705393533000_sfz034-B10","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMoa0706130","article-title":"Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis","volume":"359","author":"Gutierrez","year":"2008","journal-title":"N Engl J Med"},{"key":"2020021705393533000_sfz034-B11","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1681\/ASN.2010121224","article-title":"FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis","volume":"22","author":"Kendrick","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"2020021705393533000_sfz034-B12","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1001\/jama.2011.826","article-title":"Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease","volume":"305","author":"Isakova","year":"2011","journal-title":"JAMA"},{"key":"2020021705393533000_sfz034-B13","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2215\/CJN.03270314","article-title":"Effect of cinacalcet and vitamin D analogs on fibroblast growth factor-23 during the treatment of secondary hyperparathyroidism","volume":"10","author":"Sprague","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"2020021705393533000_sfz034-B14","first-page":"1566","article-title":"Prognostic value of bone- and vascular-derived molecular biomarkers in hemodialysis and renal transplant patients: a systematic review and meta-analysis","volume":"32","author":"Pichler","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"2020021705393533000_sfz034-B15","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.kint.2017.04.006","article-title":"Executive summary of the 2017 KDIGO chronic kidney disease-mineral and bone disorder (CKD-MBD) guideline update: what's changed and why it matters","volume":"92","author":"Ketteler","year":"2017","journal-title":". Kidney Int"},{"key":"2020021705393533000_sfz034-B16","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1093\/ndt\/gfu011","article-title":"Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study","volume":"29","author":"Cozzolino","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"2020021705393533000_sfz034-B17","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1093\/ndt\/gfr668","article-title":"Changes in fibroblast growth factor 23 during treatment of secondary hyperparathyroidism with alfacalcidol or paricalcitol","volume":"27","author":"Hansen","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"2020021705393533000_sfz034-B18","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1007\/s11255-011-0050-7","article-title":"Cinacalcet lowers FGF-23 level together with bone metabolism in hemodialyzed patients with secondary hyperparathyroidism","volume":"44","author":"Hryszko","year":"2012","journal-title":"Int Urol Nephrol"},{"key":"2020021705393533000_sfz034-B19","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2369-14-112","article-title":"Cinacalcet lowering of serum fibroblast growth factor-23 concentration may be independent from serum Ca, P, PTH and dose of active vitamin D in peritoneal dialysis patients: a randomized controlled study","volume":"14","author":"Kim","year":"2013","journal-title":"BMC Nephrol"},{"key":"2020021705393533000_sfz034-B20","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/ndt\/gfr384","article-title":"Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism","volume":"27","author":"Koizumi","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"2020021705393533000_sfz034-B21","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/ki.2010.352","article-title":"Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism","volume":"79","author":"Wesseling-Perry","year":"2011","journal-title":"Kidney Int"},{"key":"2020021705393533000_sfz034-B22","doi-asserted-by":"crossref","first-page":"110","DOI":"10.2215\/CJN.03630509","article-title":"Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD","volume":"5","author":"Wetmore","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"2020021705393533000_sfz034-B23","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1093\/ndt\/gfs018","article-title":"Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study","volume":"27","author":"Ketteler","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"2020021705393533000_sfz034-B24","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1001\/jama.2016.19456","article-title":"Effect of etelcalcetide vs placebo on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: two randomized clinical trials","volume":"317","author":"Block","year":"2017","journal-title":"JAMA"},{"key":"2020021705393533000_sfz034-B25","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1001\/jama.2016.19468","article-title":"Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial","volume":"317","author":"Block","year":"2017","journal-title":"JAMA"},{"key":"2020021705393533000_sfz034-B26","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1359\/jbmr.090406","article-title":"Effects of hPTH(1-34) infusion on circulating serum phosphate, 1,25-dihydroxyvitamin D, and FGF23 levels in healthy men","volume":"24","author":"Burnett-Bowie","year":"2009","journal-title":"J Bone Miner Res"},{"key":"2020021705393533000_sfz034-B27","doi-asserted-by":"crossref","first-page":"F882","DOI":"10.1152\/ajprenal.00360.2010","article-title":"PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop","volume":"299","author":"Lavi-Moshayoff","year":"2010","journal-title":"Am J Physiol Renal Physiol"},{"key":"2020021705393533000_sfz034-B28","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/ki.2011.107","article-title":"Direct and indirect effects of parathyroid hormone on circulating levels of fibroblast growth factor 23 in vivo","volume":"80","author":"Lopez","year":"2011","journal-title":"Kidney Int"},{"key":"2020021705393533000_sfz034-B29","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.bone.2011.06.025","article-title":"Parathyroid hormone receptor signaling in osteocytes increases the expression of fibroblast growth factor-23 in vitro and in vivo","volume":"49","author":"Rhee","year":"2011","journal-title":"Bone"},{"key":"2020021705393533000_sfz034-B30","first-page":"923","article-title":"Discovery of \u03b1-Klotho and FGF23 unveiled new insight into calcium and phosphate homeostasis","volume":"18","author":"Nabeshima","year":"2008","journal-title":"Clin Calcium"},{"key":"2020021705393533000_sfz034-B31","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1681\/ASN.2012010048","article-title":"Targeted deletion of Klotho in kidney distal tubule disrupts mineral metabolism","volume":"23","author":"Olauson","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"2020021705393533000_sfz034-B32","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.bone.2016.09.010","article-title":"FGF23-Klotho signaling axis in the kidney","volume":"100","author":"Erben","year":"2017","journal-title":"Bone"},{"key":"2020021705393533000_sfz034-B33","doi-asserted-by":"crossref","first-page":": 17","DOI":"10.5414\/CN107764","article-title":"The effect of phosphate binders, calcium and lanthanum carbonate on FGF23 levels in chronic kidney disease patients","volume":"80","author":"Soriano","year":"2013","journal-title":"Clin Nephrol"},{"key":"2020021705393533000_sfz034-B34","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1744-9987.2005.00293.x","article-title":"Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients","volume":"9","author":"Koiwa","year":"2005","journal-title":"Ther Apher Dial"},{"key":"2020021705393533000_sfz034-B35","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/nep.12319","article-title":"Long-term sevelamer treatment lowers serum fibroblast growth factor 23 accompanied with increasing serum Klotho levels in chronic haemodialysis patients","volume":"19","author":"Lin","year":"2014","journal-title":"Nephrology (Carlton)"},{"key":"2020021705393533000_sfz034-B36","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s10157-017-1510-x","article-title":"Effect of ferric citrate hydrate on FGF23 and PTH levels in patients with non-dialysis-dependent chronic kidney disease with normophosphatemia and iron deficiency","volume":"22","author":"Iguchi","year":"2018","journal-title":"Clin Exp Nephrol"},{"key":"2020021705393533000_sfz034-B37","doi-asserted-by":"crossref","first-page":"c74","DOI":"10.1159\/000319650","article-title":"Fibroblast growth factor 23 in hemodialysis patients: effects of phosphate binder, calcitriol and calcium concentration in the dialysate","volume":"117","author":"Cancela","year":"2011","journal-title":"Nephron Clin Pract"},{"key":"2020021705393533000_sfz034-B38","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1681\/ASN.2011101006","article-title":"Calcium deficiency reduces circulating levels of FGF23","volume":"23","author":"Rodriguez-Ortiz","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"2020021705393533000_sfz034-B39","doi-asserted-by":"crossref","first-page":"E310","DOI":"10.1152\/ajpendo.00460.2012","article-title":"Interactions between calcium and phosphorus in the regulation of the production of fibroblast growth factor 23 in vivo","volume":"304","author":"Quinn","year":"2013","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2020021705393533000_sfz034-B40","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1210\/jc.2009-1909","article-title":"The calcemic response to continuous parathyroid hormone (PTH)(1-34) infusion in end-stage kidney disease varies according to bone turnover: a potential role for PTH(7-84)","volume":"95","author":"Wesseling-Perry","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"2020021705393533000_sfz034-B41","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1038\/ki.2014.215","article-title":"Parathyroid hormone activates the orphan nuclear receptor Nurr1 to induce FGF23 transcription","volume":"86","author":"Meir","year":"2014","journal-title":"Kidney Int"},{"key":"2020021705393533000_sfz034-B42","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0272-6386(04)00817-0","article-title":"Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism","volume":"44","author":"Sato","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"2020021705393533000_sfz034-B43","doi-asserted-by":"crossref","first-page":"6453803","DOI":"10.1155\/2016\/6453803","article-title":"Changes in serum concentrations of fibroblast growth factor 23 and soluble klotho in hemodialysis patients after total parathyroidectomy","volume":"2016","author":"Liao","year":"2016","journal-title":"Biomed Res Int"},{"key":"2020021705393533000_sfz034-B44","article-title":"In uremic rats, the calcimimetic maintains bone turnover in a parathyroid hormone-independent manner","author":"Tocados","year":"2016","journal-title":"Annual Congress of the American Society of Nephrology"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ckj\/article-pdf\/13\/1\/75\/32500099\/sfz034.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ckj\/article-pdf\/13\/1\/75\/32500099\/sfz034.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T05:40:25Z","timestamp":1581918025000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/13\/1\/75\/5480402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,26]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,4,26]]},"published-print":{"date-parts":[[2020,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfz034","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,2]]},"published":{"date-parts":[[2019,4,26]]}}}